According to the CRYSTAL trial, combining TSC with FOLFIRI as first-line treatment reduces the risk of disease progression by 15% and extends overall survival by 8.2 months in patients with KRAS wild-type mCRC compared to those receiving FO. Here, KRAS is linked to tuberous sclerosis.